About protara therapeutics inc - TARA
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.
TARA At a Glance
Protara Therapeutics, Inc.
345 Park Avenue South
New York, New York 10010
| Phone | 1-646-844-0337 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -57,439,000.00 | |
| Sector | Health Technology | Employees | 51 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
TARA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.454 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.186 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.044 |
TARA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,126,254.902 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
TARA Liquidity
| Current Ratio | 14.581 |
| Quick Ratio | 14.581 |
| Cash Ratio | 14.22 |
TARA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -29.386 |
| Return on Equity | -31.599 |
| Return on Total Capital | -28.752 |
| Return on Invested Capital | -31.13 |
TARA Capital Structure
| Total Debt to Total Equity | 1.71 |
| Total Debt to Total Capital | 1.681 |
| Total Debt to Total Assets | 1.604 |
| Long-Term Debt to Equity | 1.078 |
| Long-Term Debt to Total Capital | 1.06 |